

Sangjune Kim

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8642200/sangjune-kim-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

28

papers

1,512

citations

13

h-index

29

g-index

29

ext. papers

2,146

ext. citations

9.3

avg, IF

4.03

L-index

#	Paper	IF	Citations
28	Transneuronal Propagation of Pathologic β Synuclein from the Gut to the Brain Models Parkinson's Disease. <i>Neuron</i> , 2019 , 103, 627-641.e7	13.9	453
27	Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease. <i>Nature Medicine</i> , 2018 , 24, 931-938	50.5	413
26	Graphene quantum dots prevent β Synucleinopathy in Parkinson's disease. <i>Nature Nanotechnology</i> , 2018 , 13, 812-818	28.7	207
25	GBA1 deficiency negatively affects physiological β Synuclein tetramers and related multimers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 798-803	11.5	106
24	β Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. <i>Molecular Neurodegeneration</i> , 2018 , 13, 1	19	63
23	The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model. <i>Human Molecular Genetics</i> , 2018 , 27, 2344-2356	5.6	34
22	Macro histone H2A1.2 (macroH2A1) protein suppresses mitotic kinase VRK1 during interphase. <i>Journal of Biological Chemistry</i> , 2012 , 287, 5278-89	5.4	33
21	Therapeutic Approaches for Inhibition of Protein Aggregation in Huntington's Disease. <i>Experimental Neurobiology</i> , 2014 , 23, 36-44	4	24
20	Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinson's disease. <i>Brain</i> , 2019 , 142, 2380-2401	11.2	21
19	Vaccinia-Related Kinase 2 Controls the Stability of the Eukaryotic Chaperonin TRiC/CCT by Inhibiting the Deubiquitinating Enzyme USP25. <i>Molecular and Cellular Biology</i> , 2015 , 35, 1754-62	4.8	21
18	Modulation of exosome-mediated mRNA turnover by interaction of GTP-binding protein 1 (GTPBP1) with its target mRNAs. <i>FASEB Journal</i> , 2011 , 25, 2757-69	0.9	20
17	Vaccinia-related kinase 2 mediates accumulation of polyglutamine aggregates via negative regulation of the chaperonin TRiC. <i>Molecular and Cellular Biology</i> , 2014 , 34, 643-52	4.8	18
16	Brazilin Isolated from <i>Caesalpinia sappan</i> suppresses nuclear envelope reassembly by inhibiting barrier-to-autointegration factor phosphorylation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015 , 352, 175-84	4.7	15
15	Preparation and evaluation of BBB-permeable trehalose derivatives as potential therapeutic agents for Huntington's disease. <i>MedChemComm</i> , 2013 , 4, 310-316	5	13
14	Protein kinase C β regulates vaccinia-related kinase 1 in DNA damage-induced apoptosis. <i>Molecular Biology of the Cell</i> , 2011 , 22, 1398-408	3.5	12
13	Stress-induced nuclear translocation of CDK5 suppresses neuronal death by downregulating ERK activation via VRK3 phosphorylation. <i>Scientific Reports</i> , 2016 , 6, 28634	4.9	11
12	Lysosomal Enzyme Glucocerebrosidase Protects against A β -42 Oligomer-Induced Neurotoxicity. <i>PLoS ONE</i> , 2015 , 10, e0143854	3.7	9

11	Glycogen synthase kinase 3 β suppresses polyglutamine aggregation by inhibiting Vaccinia-related kinase 2 activity. <i>Scientific Reports</i> , 2016 , 6, 29097	4.9	9
10	Vaccinia-related kinase 2 plays a critical role in microglia-mediated synapse elimination during neurodevelopment. <i>Glia</i> , 2019 , 67, 1667-1679	9	7
9	Vaccinia-related kinase 2 modulates role of dysbindin by regulating protein stability. <i>Journal of Neurochemistry</i> , 2018 , 147, 609-625	6	4
8	Complement and Coagulation Cascades are Potentially Involved in Dopaminergic Neurodegeneration in β Synuclein-Based Mouse Models of Parkinson's Disease. <i>Journal of Proteome Research</i> , 2021 , 20, 3428-3443	5.6	4
7	A Novel, Selective c-Abl Inhibitor, Compound 5, Prevents Neurodegeneration in Parkinson's Disease. <i>Journal of Medicinal Chemistry</i> , 2021 , 64, 15091-15110	8.3	4
6	Dopamine D1 Receptor (D1R) Expression Is Controlled by a Transcriptional Repressor Complex Containing DISC1. <i>Molecular Neurobiology</i> , 2019 , 56, 6725-6735	6.2	3
5	Mutant glucocerebrosidase impairs β Synuclein degradation by blockade of chaperone-mediated autophagy.. <i>Science Advances</i> , 2022 , 8, eabm6393	14.3	3
4	Cell-Based Screen Using Amyloid Mimic β 3 Expression Identifies Peucedanocoumarin III as a Novel Inhibitor of β Synuclein and Huntingtin Aggregates. <i>Molecules and Cells</i> , 2019 , 42, 480-494	3.5	2
3	Complement and coagulation cascades are potentially involved in dopaminergic neurodegeneration in β Synuclein-based mouse models of Parkinson's disease		2
2	TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinson's disease. <i>Neuron</i> , 2021 , 109, 3758-3774.e11	13.9	1
1	HNRNP Q suppresses polyglutamine huntingtin aggregation by post-transcriptional regulation of vaccinia-related kinase 2. <i>Journal of Neurochemistry</i> , 2019 , 149, 413-426	6	0